|Water solubility||Soluble in water|
|Storage||Store at regular temperature|
|Color||White to off-white|
|Packing||PE bag+Aluminum bag|
poly-1(2/3)-n-acetyl-2-amino-2-deoxy-3-o-beta-d-glucopyranurosyl-4-(6)sulfonyl-d-galactose; chondroitinpoly sulfate; chondroitin sulfates; chondroiti nsulfuricacid; chondroitin sulfuric acids; chonsurid; CSO;(5ξ)-2-(Carboxyamino)-2-deoxy-3-O-β-D-glucopyranuronosyl-4-O-sulfo-α-L-arabino-hexopyranose
Chondroitinsulfate (CS) is an acidic mucopolysaccharide extracted and purified from animal cartilage tissue. Chondroitin sulfate has different structures such as A, C, D, E, H and K. Chondroitin sulfate in nature is mostly found in animal cartilage, throat bone, nasal bone (41% in pigs), bovine, horse septum and trachea (containing 36% to 39%), other tissues such as leg bones, ligaments, skin, cornea, etc. are also contained. The content of fish cartilage is very rich, such as 50% to 60% in shark bone, and very little in connective tissue.
For coronary atherosclerotic disease, increased blood lipids and cholesterol, arteriosclerosis, angina pectoris, myocardial ischemia, myocardial infarction, etc. in patients with coronary heart disease.
Rapamycin (RAPA) has similar side effects to FK506. In a large number of clinical trials, its side effects were found to be dose-dependent and reversible, and RAPA at therapeutic doses has not been found to have significant nephrotoxicity and no gingival hyperplasia. The main toxic and side effects include: headache, nausea, dizziness, nosebleeds, and joint pain. Laboratory abnormalities include: thrombocytopenia, leukopenia, low hemoglobin, hypertriglyceridemia, hypercholesterolemia, hyperglycemia, elevated liver enzymes (SGOT, SGPT), elevated lactate dehydrogenase, hypokalemia, Hypomagnesemia, etc. Eyelid edema was recently reported with RAPA administration, and the cause of lower plasma phosphate levels is thought to be prolonged phosphate excretion from the transplanted kidney by RAPA-based immunosuppressive therapy. Like other immunosuppressants, RAPA has an increased chance of infection, with a reported tendency to increase pneumonia in particular, but the occurrence of other opportunistic infections is not significantly different from CsA.
Chondroitin sulfate widely exists in human and animal cartilage tissue. The medicinal preparation mainly contains two isomers of chondroitin sulfate A and chondroitin sulfate C, and the content of chondroitin sulfate in the cartilage of animals of different breeds and ages is different. Its pharmacological effects are as follows: chondroitin sulfate can remove lipids and lipoproteins in the blood, remove cholesterol from blood vessels around the heart, prevent and treat atherosclerosis, and increase the conversion rate of lipids and fatty acids in cells. Chondroitin sulfate can effectively prevent and treat coronary heart disease. It has anti-atherosclerosis and anti-atherogenic plaque formation effects on experimental arteriosclerosis models; increases the coronary branches or collateral circulation of atherosclerosis, and can accelerate experimental coronary arteriosclerosis or embolism. Healing, regeneration and repair of myocardial necrosis or degeneration. It can increase the biosynthesis of cell messenger ribonucleic acid (mRNA) and deoxyribonucleic acid (DNA) and has the effect of promoting cell metabolism. Low anticoagulant activity. Chondroitin sulfate has a moderate anticoagulant effect, and each 1 mg of chondroitin sulfate A is equivalent to the anticoagulant activity of 0.45U of heparin. This anticoagulant activity does not depend on antithrombin III to play its role, it can exert anticoagulant activity through the fibrinogen system. Chondroitin sulfate also has anti-inflammatory, accelerated wound healing and anti-tumor effects.